Evidence map›Paper›PMID 20015980›Full record

ArticleJournal of virology2010

Combined administration with DNA encoding vesicular stomatitis virus G protein enhances DNA vaccine potency.

Chih-Ping Mao, Chien-Fu Hung, Tae Heung Kang, Liangmei He, Ya-Chea Tsai, Chao-Yi Wu, T-C Wu

Abstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Systemic delivery of fusogenic membrane glycoprotein-expressing neural stem cells to selectively kill tumor cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2013
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Chih-Ping MaoDepartment of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA.
Chien-Fu Hung
Tae Heung Kang
Liangmei He
Ya-Chea Tsai
Chao-Yi Wu
T-C Wu
Beijing Obstetrics and Gynecology Hospital · CN

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
Geosocial Health Disparities: Temporal AnalysesR03CA115245 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHEN, JARVIS T · 2005 to 2006
$162k
NCI NIH HHS 1 R01 CA115245-01NCI NIH HHS P50 CA098252NCI NIH HHS R03 CA115245
6 · The paper itself

Abstract

DNA vaccines have recently emerged at the forefront of approaches to harness the immune system in the prevention and treatment of viral infections, as well as the prevention and treatment of cancers. However, these vaccines suffer from limited efficacy since they often fail to produce significant antigen-specific CD8(+) T-cell responses. We report here a novel concept for DNA vaccine design that exploits the unique and powerful ability of viral fusogenic membrane glycoproteins (FMGs) to couple concentrated antigen transfer to dendritic cells (DCs) with local induction of the acute inflammatory response. Intramuscular administration into mice by electroporation technology of a plasmid containing the FMG gene from vesicular stomatitis virus (VSV-G)-together with DNA encoding the E7 protein of human papillomavirus type 16, a model cervical cancer antigen-elicited robust E7-specific CD8(+) T-cell responses, as well as therapeutic control of E7-expressing tumors. This effect could potentially be mediated through the immunogenic form of cellular fusion and necrosis induced by VSV-G, which in a concerted fashion provokes leukocyte infiltration into the inoculation site, enhances cross-presentation of antigen to DCs, and stimulates them to mature efficiently. Thus, the incorporation of FMGs into DNA vaccines holds promise for the successful control of viral infections and cancers in the clinic.

Indexed as

Vaccines, DNAAnimalsAntigens, ViralCD8-Positive T-LymphocytesCell DeathCell FusionCells, CulturedDendritic CellsDNA, ViralFemaleHumansInterferon-gammaMembrane GlycoproteinsMiceMice, Inbred C57BLMuscle, SkeletalAntigens, ViralDNA, ViralG protein, vesicular stomatitis virusInterferon-gammaMembrane Glycoproteinsoncogene protein E7, Human papillomavirus type 16Oncogene Proteins, ViralPapillomavirus E7 ProteinsVaccines, DNAViral Envelope Proteins

Identifiers

PMID20015980
PMCPMC2820938
OpenAlexW2083738876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.